Pipeline

Complementary platforms that act alone or in combination with other treatments to treat cancer and chronic diseases.

Nibrozetone (RRx-001) Program: CAN Pipeline

Cancer
Study Indication Preclinical Phase 1 Phase 2 Phase 3
REPLATINUM SCLC
KEVLARx Severe Oral Mucositis
ROCKET Metastatic colorectal cancer
Anti Endometriosis
Study Indication Preclinical Phase 1 Phase 2 Phase 3
In Start-up Endometriosis
Progressive Neurodegenerative Diseases
Indication Grants Preclinical
Parkinson’s Michael J Fox Foundation Therapeutic Pipeline Program
ALS/MND FightMND Drug Development Program Grant
Neuroprotection Awarded - to be announced
Gulf War Illness Awarded - to be announced

AdAPT (AdAPT-001) Program: Targeting TGF-beta

AdAPT-001 TGF-beta Inhibitor Program
Study Indication Preclinical Phase 1 Phase 2 Phase 3
BETA PRIME Sarcoma & Solid Tumors
TBA
Active programs

Partnership Opportunities: We welcome regional and global partnerships with like-minded companies, institutions, and investors that support our first-in-class therapies and treatment programs in oncology, radioprotection, and neurodegenerative and gynecological diseases.